EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
http://acne.gd/acne-kits-that-work-2/ You may have suffered acne breakouts as a teen, or you may be struggling with it presently.
You will find a lot of alternative choices for this common skin condition, you just have to know which therapy will work greatest for you.
The launch of the fall television season is underway and with it, the influx of commercial interruptions. Lexus is offering an alternative to the traditional 30-minute sitcom with the debut of its fourth season of L Studio. The popular broadband channel, which has delivered such award-winning entertainment as “Web Therapy” and “Puppy Love,” is now partnering with Academy Award-winning screenwriter Diablo Cody (“Juno”) to debut her Web series “Red Band Trailer.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/52359-lexus-l-studio-diablo-cody-red-band-trailer-celebrity-interviews
Approximately 80 million American men and women experience some form of hair loss. Premature balding or thinning hair can often result in a decrease of self esteem. Freedom Laser Therapy of Los Angeles is dedicated to change all that by bringing their iRestore Hair Rejuvenation System to the mass market.
This proven, safe Laser Hair Restoration Technology, otherwise known as phototherapy, is a scientific process providing stimulation to cells in your hair. The 25-year old advanced low-level laser treatment stimulates the scalp, allowing miniaturized and dormant hair follicles to rejuvenate.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54394-freedom-laser-therapy-laser-hair-treatment-regrowth-restoration
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI), is introducing its latest advancement in oxygen therapy. SimplyGo is the only portable oxygen concentrator (POC) to offer continuous flow (up to 2 liters per minute) and pulse-dose delivery in a single device weighing 10 pounds or less. With this combination of capabilities, the SimplyGo POC helps homecare providers manage the therapy and lifestyle needs of nearly all oxygen users.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54713-philips-respironics-simplygo-portable-oxygen-concentrator
http://acne.gd/clear-remedy/
I am glad I was in a position to attempt this item with a reduced cost, because frankly it did not reside up to its billing. The therapy system is according to salicylic acid and other
Superstar model, producer, television host and designer, Heidi Klum is known for her cutting-edge style and trademark tresses. Now Unilever is tapping the sophisticated fashion icon to help launch new CLEAR SCALP & HAIR BEAUTY THERAPY™, a revolutionary line of nourishing shampoos and conditioners that turns the conventional hair care discussion on its head. This new approach “feeds scalp,” not just the ends, and gives women stronger, more beautiful hair in just seven days.
“When it comes to women’s hair care, the emphasis has traditionally been on the ends, yet 99 percent of hair’s natural strength and beauty comes from the scalp. Scalp is skin and it is important to care for and nourish it just as we care for our skin. NEW CLEAR SCALP & HAIR BEAUTY THERAPY™ feeds the scalp and creates the right foundation for stronger, more beautiful hair in just seven days,” says David Rubin, U.S. Haircare Marketing Director for Unilever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55843-clear-scalp-and-hair-therapy
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
